Back to results
US 8,273,538 B2Granted
Blood monocyte CD163 expression as a biomarker in HIV-1 infection and neuroaids
AssigneeTemple University of the Commonwealth System of Higher Education
InventorsJay Rappaport, Tracy Fischer-Smith
Life of this patent
Estimating the term…
Abstract
The invention provides a method for detecting CD163+/CD16+ cell population in peripheral blood mononuclear cells in a biological sample from a subject infected with HIV-1 which comprises contacting the biological sample with an anti-CD163 antibody, so that levels of CD163+/CD16+ peripheral blood mononuclear cells in the biological sample can be quantified. The method of the present invention is particularly useful for monitoring the course of HIV-1 infection and/or HIV Encephalopathy
Claims7
A method for determining the risk of neurological manifestations of HIV infection in an HIV-1-infected subject, comprising:
- (a) obtaining a first blood, serum, or plasma sample from the subject;
- (b) determining from the first blood, serum, or plasma sample a fraction of CD163+/CD16+ monocytes in a population of peripheral blood mononuclear cells, an HIV-1 viral load, and a CD4+ T cell count;
- (c) at a different time, obtaining a subsequent blood, serum, or plasma sample from the subject;
- and
- (d) determining from the subsequent blood, serum, or plasma sample a fraction of CD163+/CD16+ monocytes in a population of peripheral blood mononuclear cells, an HIV-1 viral load, and a CD4+ T cell count;
- wherein when the fractions of CD163+/CD16+ monocytes in peripheral blood mononuclear cells and the HIV-1 viral loads in steps (b) and (d) are above a baseline fraction and a baseline HIV-1 viral load in healthy seronegative subjects respectively while the CD4+ T cell counts in steps (b) and (d) are below a baseline count in healthy seronegative subjects, this is indicative of the risk of neurological manifestations of HIV infection in the HIV-1-infected subject.
3 more elements
A method for determining the risk of CNS invasion by HIV-1 virus in HIV-1-positive subjects comprising:
- (a) obtaining a first blood, serum, or plasma sample from the subject,
- (b) determining from the first blood, serum, or plasma sample a fraction of CD 163+/CD16+ monocytes in peripheral blood mononuclear cells, an HIV-1 viral load, and a CD4+ T cell count of the subject,
- (c) at a different time, obtaining a subsequent blood, serum, or plasma sample from the subject;
- and
- (d) determining from the subsequent blood, serum, or plasma sample a fraction of CD163+/CD16+ monocytes in peripheral blood mononuclear cells, an HIV-1 viral load, and a CD4+ T cell count of the subject;
- wherein when the fractions of CD163+/CD16+ monocytes in peripheral blood mononuclear cells and the HIV-1 viral loads in steps (b) and (d) are above a baseline fraction and a baseline HIV-1 viral load in healthy seronegative subjects respectively while the CD4+ T cell counts in steps (b) and (d) are below a baseline count in healthy seronegative subjects, this is indicative of a risk of CNS invasion by said virus.
3 more elements
A method for predicting HIV-1 disease progression in an HIV-1-positive subject comprising:
- (a) obtaining a first blood, serum, or plasma sample from the subject;
- (b) determining from the first blood, serum, or plasma sample a fraction of CD 163+/CD16+ monocytes in peripheral blood mononuclear cells, an HIV-1 viral load, and a CD4+ T cell count;
- (c) at a different time, obtaining a subsequent blood, serum, or plasma sample from the subject;
- and
- (d) determining from the subsequent blood, serum, or plasma sample a fraction of CD163+/CD16+ monocytes in peripheral blood mononuclear cells, an HIV-1 viral load, and a CD4+ T cell count;
- wherein when the fractions of CD163+/CD16+ monocytes in peripheral blood mononuclear cells and the HIV-1 viral loads in steps (b) and (d) are above a baseline fraction and a baseline HIV-1 viral load in healthy seronegative subjects respectively while the CD4+ T cell counts in steps (b) and (d) are below a baseline count in healthy seronegative subjects, this is predictive of HIV-1 disease progression in the HIV-1-positive subject.
3 more elements
A method for monitoring a viral load of an HIV-infected subject comprising:
- (a) obtaining a first blood, serum, or plasma sample from the subject;
- (b) determining from the first blood, serum, or plasma sample a fraction of CD 163+/CD16+ monocytes in peripheral blood mononuclear cells;
- (c) at a different time, obtaining a subsequent blood, serum, or plasma sample from the subject;
- and
- (d) determining from the subsequent blood, serum, or plasma sample a fraction of CD163+/CD16+ monocytes in peripheral blood mononuclear cells of the subject;
- wherein when the fractions of CD163+/CD16+ monocytes in peripheral blood mononuclear cells in steps (b) and (d) are above a baseline fraction in healthy seronegative subjects, this is indicative of an increased HIV-1 viral load in the HIV-1-positive subject.
3 more elements
A method for determining a risk of disease progression in an HIV-infected subject comprising:
- (a) obtaining a first blood, serum, or plasma sample from the subject;
- (b) determining from the first blood, serum, or plasma sample a fraction of CD163+/CD16+ monocytes in peripheral blood mononuclear cells, an HIV-1 viral load, and a CD4+ T cell count;
- (c) at a different time, obtaining a subsequent blood, serum, or plasma sample from the subject;
- and
- (d) determining from the subsequent blood, serum, or plasma sample a fraction of CD163+/CD16+ monocytes in peripheral blood mononuclear cells, an HIV-1 viral load, and a CD4+ T cell count of the subject;
- wherein when the fractions of CD163+/CD16+ monocytes in peripheral blood mononuclear cells and the HIV-1 viral loads in steps (b) and (d) are above a baseline fraction and a baseline HIV-1 viral load in healthy seronegative subjects respectively while the CD4+ T cell counts in steps (b) and (d) are below a baseline count in healthy seronegative subjects, this is indicative of an increased risk of disease progression in the HIV-infected subject.
3 more elements
A method for determining a risk of development of HIV encephalopathy in an HIV-infected subject comprising:
- (a) obtaining a first blood, serum, or plasma sample from the subject;
- (b) determining from the first blood, serum, or plasma sample a fraction of CD 163+/CD16+ monocytes in peripheral blood mononuclear cells, an HIV-1 viral load, and a CD4+ T cell count;
- (c) at a different time, obtaining a subsequent blood, serum, or plasma sample from the subject;
- and
- (d) determining from the subsequent blood, serum, or plasma sample a fraction of CD163+/CD16+ monocytes in peripheral blood mononuclear cells, an HIV-1 viral load, and a CD4+ T cell count;
- wherein when the fractions of CD163+/CD16+ monocytes in peripheral blood mononuclear cells and the HIV-1 viral loads in steps (b) and (d) are above a baseline fraction and a baseline HIV-1 viral load in healthy seronegative subjects respectively while the CD4+ T cell counts in steps (b) and (d) are below a baseline count in healthy seronegative subjects, this is indicative of an increased risk of development of HIV encephalopathy in the HIV-infected subject.
3 more elements
Dependencies are inferred from the claim text.